LipoBridge^® is an innovative technology specifically designed to facilitate transport of drug compounds across the blood brain barrier (BBB) and into the central nervous system (CNS).

LipoMask^TM increases the circulation half life of lipid particles in blood, thereby tailoring drug pharmacokinetic profiles, improving drug efficacy, and decreasing drug toxicity.

Design for Peptide Delivery^SM is a concept developed by the Brookwood - Genzyme Pharmaceuticals Collaboration to address formulation issues often overlooked during peptide discovery. This service renders active substances more suitable for formulation and sustained drug delivery for companies working in discovery and early stage development. This may be done by modifying the chemical and/or physical properties of the peptide Active Pharmaceutical Ingredient (API) as well as adapting the delivery system to achieve the desired release profile for the drug.

Cerense^SM, developed by Genzyme Pharmaceuticals and Pharmidex Ltd., is the world’s first integrated solution to release the value of your CNS portfolio by unlocking the blood-brain barrier and measuring brain penetration. This is achieved through the combination of Genzyme Pharmaceuticals’ patented LipoBridge^®  CNS drug delivery technology and the unique expertise of Pharmidex to determine neuropharmacokinetics.